Retrospective Analysis for Patients With Metabolic Syndrome

December 24, 2023 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University

Retrospective Analysis of Outpatient Intervention Effects in Patients With Metabolic Syndrome

The incidence of metabolic syndrome and related diseases is gradually increasing, and diet and medication are currently common outpatient treatment methods. This study retrospectively analyzes the clinical data of patients with metabolic syndrome and related diseases who have visited our outpatient department in the past 10 years, compares the therapeutic effects of different treatment methods on their blood glucose, blood lipids, blood pressure, uric acid, and body composition, and provides evidence support for clinical treatment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310009
        • Recruiting
        • The Second Affiliated Hospital, College of Medicine, Zhejiang University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

This was a retrospective study of the weight loss effect in 1 to 3 months in overweight or obese individuals at the department of clinical nutrition in the Second Affiliated Hospital of Zhejiang University, School of Medicine in China between 1 January 2020 and 1 Janu-ary 2024.

Description

Inclusion Criteria:

• individuals who had at least a 2 follow up visits with a BMI of 24 or more with the pri-mary goal of losing weight.

Exclusion Criteria:

  • patients did not follow-up on a monthly basis;
  • patients followed-up less than 1 times within 3 months;
  • patients having incomplete data;
  • patients changing their interventions during fol-low-ups

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
low-carbohydrate diet
20-30% carbohydrates, 40-45%fat, and 30-40%protein
Other: dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss
balanced diet
50-65% carbohydrate, 20-30% fat and 10-20% protein
Other: dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss
pharmacotherapy
semaglutide (1mg per week) or/and metformin (o.5g three times a day)
Other: dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
weight
Time Frame: 0month/1month/2months/3 months
Weight was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points
0month/1month/2months/3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
visceral fat area(VFA)
Time Frame: 0month/1month/2months/3 months
VFA was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points
0month/1month/2months/3 months
skeletal muscle mass(SMM)
Time Frame: 0month/1month/2months/3 months
SMM was measured through multi-frequency bioelectrical impedance analysis InBody 720 (Bio Space Co., Seoul, Korea) at various time points
0month/1month/2months/3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2023

Primary Completion (Estimated)

January 1, 2024

Study Completion (Estimated)

January 1, 2024

Study Registration Dates

First Submitted

November 30, 2023

First Submitted That Met QC Criteria

December 24, 2023

First Posted (Actual)

December 27, 2023

Study Record Updates

Last Update Posted (Actual)

December 27, 2023

Last Update Submitted That Met QC Criteria

December 24, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023-1042

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Syndrome

Clinical Trials on dietary, semaglutide or/and metformin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe